Thalidomide and its dermatologic uses

American Journal of the Medical Sciences

Volumn 321, Issue 5, 2001, Pages 321-326

  Moraes, Michele ^a   Russo, Glenn ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatology; Thalidomide

Indexed keywords

GLUTAMIC ACID; THALIDOMIDE;

APHTHOUS ULCER; BEHCET DISEASE; CONFERENCE PAPER; DISCOID LUPUS ERYTHEMATOSUS; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS; HUMAN; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; PYODERMA GANGRENOSUM; SARCOIDOSIS; SKIN DISEASE; UNITED STATES;

EID: 0035023334     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200105000-00004     Document Type: Conference Paper

References (44)

1. Peculiarities and possible mode of actions of thalidomide
2. The saga of thalidomide
3. Thalidomide in the treatment of lepra reactions
4. Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions
5. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite
6. Teratogen update: Clinical aspects of thalidomide embryopathy - A continuing preoccupation
7. Cellular immune effects of thalidomide in actinic prurigo
8. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin
9. Inhibition of PMN leukocytes chemotaxis by thalidomide
10. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes
11. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states
12. Thalidomide-effect on T cell subsets as a possible mechanism of action
13. Tumor necrosis factor production in patients with leprosy
14. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation
15. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes
16. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
17. Cytokine regulation of disease progression in leprosy and tuberculosis
18. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood
19. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
20. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
21. Chronic cutaneous lupus erythematosus treated with thalidomide
22. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review
23. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
24. Cutaneous sarcoidosis successfully treated with low doses of thalidomide
25. Thalidomide in the treatment of Behcet's syndrome
26. Behcet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide
27. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's syndrome. A randomized, double-blind, placebo-controlled trial
28. Thalidomide for the treatment of chronic graft-versus-host disease
29. Successful treatment with thalidomide of acute graft-versus-host disease after bone marrow transplantation
30. Thalidomide for graft-versus-host disease after bone marrow transplantation
31. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody
32. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis
33. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: Successful treatment with thalidomide
34. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
35. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial
36. Erosive lichen planus: Dramatic response to thalidomide
37. Recalcitrant pyoderma gangrenosum: Treatment with thalidomide
38. Thalidomide and its impact in dermatology
39. Does thalidomide affect IL-2 response and production?
40. Treatment of refractory rheumatoid arthritis - The thalidomide experience